NASDAQ:CSBR - Champions Oncology Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$12.59 +0.51 (+4.22 %)
(As of 11/16/2018 03:05 AM ET)
Previous Close$12.08
Today's Range$11.56 - $12.74
52-Week Range$3.05 - $17.90
Volume61,400 shs
Average Volume113,181 shs
Market Capitalization$145.03 million
P/E Ratio-89.93
Dividend YieldN/A
Beta0.57
Champions Oncology, Inc. develops and sells technology solutions and products to personalize the development and use of oncology drugs in the United States. Its Tumorgraft Technology Platform is an approach to personalizing cancer care based upon the implantation of human tumors in immune-deficient mice. The company, through its Tumorgraft Technology Platform, provides Personalized Oncology Solutions (POS) that assist physicians in developing personalized treatment options for cancer patients through tumor specific data obtained from drug panels and related personalized oncology services. The company also offers POS products, including personalized tumor boards that are designed to provide access to oncologists with expertise in particular tumor types; and provides access to gene sequencing that analyzes the genetic makeup of patient's tumor for the purpose of identifying potentially useful drugs. In addition, it offers Translational Oncology Solutions, including a preclinical Tumorgraft platform to pharmaceutical and biotechnology companies. Champions Oncology, Inc. markets its products through Internet, word of mouth, and sales force to patients and physicians. The company was formerly known as Champions Biotechnology, Inc. and changed its name to Champions Oncology, Inc. in April 2011 to reflect its new focus on developing technologies to personalize the development and use of oncology drugs. Champions Oncology, Inc. was incorporated in 1985 and is headquartered in Hackensack, New Jersey.

Receive CSBR News and Ratings via Email

Sign-up to receive the latest news and ratings for CSBR and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:CSBR
Previous Symbol
CUSIPN/A
Phone201-808-8400

Debt

Debt-to-Equity Ratio0.23
Current Ratio0.73
Quick Ratio0.73

Price-To-Earnings

Trailing P/E Ratio-89.93
Forward P/E Ratio74.06
P/E GrowthN/A

Sales & Book Value

Annual Sales$20.24 million
Price / Sales6.94
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A

Profitability

EPS (Most Recent Fiscal Year)($0.14)
Net Income$-1,470,000.00
Net Margins-1.63%
Return on Equity-97.02%
Return on Assets-4.66%

Miscellaneous

Employees92
Outstanding Shares11,160,000
Market Cap$145.03 million
OptionableNot Optionable

Champions Oncology (NASDAQ:CSBR) Frequently Asked Questions

What is Champions Oncology's stock symbol?

Champions Oncology trades on the NASDAQ under the ticker symbol "CSBR."

How were Champions Oncology's earnings last quarter?

Champions Oncology Inc (NASDAQ:CSBR) posted its quarterly earnings data on Thursday, September, 13th. The biotechnology company reported $0.04 EPS for the quarter, beating the Zacks' consensus estimate of $0.01 by $0.03. The biotechnology company earned $6.23 million during the quarter, compared to the consensus estimate of $5.85 million. Champions Oncology had a negative net margin of 1.63% and a negative return on equity of 97.02%. View Champions Oncology's Earnings History.

When is Champions Oncology's next earnings date?

Champions Oncology is scheduled to release their next quarterly earnings announcement on Thursday, December 6th 2018. View Earnings Estimates for Champions Oncology.

What price target have analysts set for CSBR?

3 brokerages have issued twelve-month target prices for Champions Oncology's stock. Their forecasts range from $10.00 to $12.00. On average, they anticipate Champions Oncology's share price to reach $11.00 in the next year. This suggests that the stock has a possible downside of 12.6%. View Analyst Price Targets for Champions Oncology.

What is the consensus analysts' recommendation for Champions Oncology?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Champions Oncology in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Champions Oncology.

Has Champions Oncology been receiving favorable news coverage?

News coverage about CSBR stock has trended extremely positive this week, according to InfoTrie Sentiment Analysis. InfoTrie rates the sentiment of press coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Champions Oncology earned a media sentiment score of 4.2 on InfoTrie's scale. They also assigned media coverage about the biotechnology company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an effect on the company's share price in the near term.

Who are some of Champions Oncology's key competitors?

Who are Champions Oncology's key executives?

Champions Oncology's management team includes the folowing people:
  • Dr. Ronnie Morris, CEO & Director (Age 52)
  • Mr. David Barry Miller, Chief Financial Officer (Age 49)
  • Mr. Mark Weinstein, Chief Information Officer
  • Dr. Angela M. Davies M.D., FRCPC, Chief Medical Officer (Age 48)
  • Dr. Neal Goodwin, VP of Corp. Research Devel.

Who are Champions Oncology's major shareholders?

Champions Oncology's stock is owned by a variety of of institutional and retail investors. Top institutional investors include Renaissance Technologies LLC (2.38%), Perkins Capital Management Inc. (1.62%), EAM Investors LLC (1.61%), Ingalls & Snyder LLC (1.42%), JPMorgan Chase & Co. (1.11%) and JPMorgan Chase & Co. (1.11%). Company insiders that own Champions Oncology stock include Daniel Newman Mendelson, Joel Ackerman and Ronnie Morris. View Institutional Ownership Trends for Champions Oncology.

Which major investors are selling Champions Oncology stock?

CSBR stock was sold by a variety of institutional investors in the last quarter, including Tocqueville Asset Management L.P. and Essex Investment Management Co. LLC. Company insiders that have sold Champions Oncology company stock in the last year include Daniel Newman Mendelson and Joel Ackerman. View Insider Buying and Selling for Champions Oncology.

Which major investors are buying Champions Oncology stock?

CSBR stock was acquired by a variety of institutional investors in the last quarter, including EAM Investors LLC, Renaissance Technologies LLC, Ingalls & Snyder LLC, JPMorgan Chase & Co., JPMorgan Chase & Co., BlackRock Inc., EAM Global Investors LLC and Perkins Capital Management Inc.. View Insider Buying and Selling for Champions Oncology.

How do I buy shares of Champions Oncology?

Shares of CSBR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Champions Oncology's stock price today?

One share of CSBR stock can currently be purchased for approximately $12.59.

How big of a company is Champions Oncology?

Champions Oncology has a market capitalization of $145.03 million and generates $20.24 million in revenue each year. The biotechnology company earns $-1,470,000.00 in net income (profit) each year or ($0.14) on an earnings per share basis. Champions Oncology employs 92 workers across the globe.

What is Champions Oncology's official website?

The official website for Champions Oncology is http://www.championsoncology.com.

How can I contact Champions Oncology?

Champions Oncology's mailing address is One University Plaza Suite 307, Hackensack NJ, 07601. The biotechnology company can be reached via phone at 201-808-8400 or via email at [email protected]


MarketBeat Community Rating for Champions Oncology (NASDAQ CSBR)

Community Ranking:  2.2 out of 5 (star star)
Outperform Votes:  86 (Vote Outperform)
Underperform Votes:  110 (Vote Underperform)
Total Votes:  196
MarketBeat's community ratings are surveys of what our community members think about Champions Oncology and other stocks. Vote "Outperform" if you believe CSBR will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CSBR will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 11/16/2018 by MarketBeat.com Staff

Featured Article: What is a Swap?

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel